Vermillion Wins Medi-Cal Coverage for OVA1 | GenomeWeb

NEW YORK (GenomeWeb) – Vermillion said today that Medi-Cal, California's Medicaid program, now supports the company's OVA1 ovarian cancer test in its medical policy guidelines.

According to Vermillion, Medi-Cal covers more than 12.6 million lives, or roughly a third of the covered lives in California.

OVA1 measures levels of five proteins in patient blood and is intended for triaging patients with ovarian adnexal masses as part of preoperative evaluations to determine the likelihood that a mass is cancerous.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.